Efficacy and Adverse Effects of the Antiviral Compound Plerixafor in Feline Immunodeficiency Virus-Infected Cats

Journal of Veterinary Internal Medicine

Volumn 26, Issue 3, 2012, Pages 483-490

  Hartmann, K ^a   Stengel, C ^a   Klein, D ^b   Egberink, H ^c   Balzarini, J ^d  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c UTRECHT UNIVERSITY   (Netherlands)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

AMD3100; Bicyclam; CXCR4; FIV

Indexed keywords

ADEFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CXCR4; DRUG DERIVATIVE; HETEROCYCLIC COMPOUND; PHOSPHONIC ACID DERIVATIVE; PLERIXAFOR;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD CELL COUNT; CAT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; FELINE IMMUNODEFICIENCY VIRUS; FEMALE; MALE; NONPARAMETRIC TEST; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ANIMALS; ANTI-HIV AGENTS; BLOOD CELL COUNT; CATS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; FEMALE; HETEROCYCLIC COMPOUNDS; IMMUNODEFICIENCY VIRUS, FELINE; MALE; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; RECEPTORS, CXCR4; STATISTICS, NONPARAMETRIC; VIRAL LOAD; VIRUS REPLICATION;

ANIMALIA; FELINE IMMUNODEFICIENCY VIRUS;

EID: 84860554718     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2012.00904.x     Document Type: Article

References (46)

1. Pedersen NC, Ho EW, Brown ML, et al. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987;235:790-793.
2. Hartmann K. Feline immunodeficiency virus infection -causative agent of an acquired immunodeficiency syndrome in cats. Eur J Med Res 1996;1:547-550.
3. Rucker J, Edinger AL, Sharron M, et al. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol 1997;71:8999-9007.
4. Willett BJ, Picard L, Hosie MJ, et al. Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses. J Virol 1997;71:6407-6415.
5. Wells TN, Proudfoot AE, Power CA, et al. Chemokine receptors - the new frontier for AIDS research. Chem Biol 1996;3:603-609.
6. Bleul CC, Wu L, Hoxie JA, et al. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997;94:1925-1930.
7. + T cells by using CD134 as a binding receptor. Proc Natl Acad Sci USA 2004;101:13044-13049.
8. Howard OM, Korte T, Tarasova NI, et al. Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function. J Leukoc Biol 1998;64:6-13.
9. Mizukoshi F, Baba K, Goto-Koshino Y, et al. Inhibitory effect of newly developed CXC-chemokine receptor 4 antagonists on the infection with feline immunodeficiency virus. J Vet Med Sci 2009;71:121-124.
10. Schols D, Este JA, Henson G, et al. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997;35:147-156.
11. Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998;4:72-77.
12. Egberink HF, De Clercq E, Van Vliet AL, et al. Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication. J Virol 1999;73:6346-6352.
13. Sundstrom M, White RL, de Parseval A, et al. Mapping of the CXCR4 binding site within variable region 3 of the feline immunodeficiency virus surface glycoprotein. J Virol 2008;82:9134-9142.
14. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-2730.
15. + T-regulatory cells correlates both with surface expression of CXCR4 and activation of FIV long terminal repeat binding cellular transcriptional factors. J Virol 2005;79:4965-4976.
16. Hart JE, Jeon CY, Ivers LC, et al. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: A meta-analysis and systematic review. J Acquir Immune Defic Syndr 2010;54:167-179.
17. Hartmann K, Donath A, Beer B, et al. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet Immunol Immunopathol 1992;35:167-175.
18. Hartmann K. AZT in the treatment of feline immunodeficiency virus infection: Part 2. Feline Pract 1995;23:13-20.
19. Arai M, Earl DD, Yamamoto JK. Is AZT/3TC therapy effective against FIV infection or immunopathogenesis? Vet Immunol Immunopathol 2002;85:189-204.
20. Huebner J, Klein D, Mueller E, et al. Kombinierte anti-retrovirale Therapie (GART) bei einer mit dem felinen ImmunschwxE4chevirus (FIV)-infizierten Katze. Kleintierpraxis 2004;49:517-524.
21. Hartmann K, Kuffer M. Karnofsky's score modified for cats. Eur J Med Res 1998;3:95-98.
22. Hoffmann-Fezer G, Thum I, Herbold M, et al. [T-helper and T-suppressor lymphocyte subpopulations in the peripheral blood of spontaneously FIV-positive cats]. Tierarztl Prax 1991;19:682-686.
23. Steinrigl A, Klein D. Phylogenetic analysis of feline immunodeficiency virus in Central Europe: A prerequisite for vaccination and molecular diagnostics. J Gen Virol 2003;84:1301-1307.
24. Klein D, Janda P, Steinborn R, et al. Proviral load determination of different feline immunodeficiency virus isolates using real-time polymerase chain reaction: Influence of mismatches on quantification. Electrophoresis 1999;20:291-299.
25. Klein D, Leutenegger CM, Bahula C, et al. Influence of preassay and sequence variations on viral load determination by a multiplex real-time reverse transcriptase-polymerase chain reaction for feline immunodeficiency virus. J Acquir Immune Defic Syndr 2001;26:8-20.
26. Klein D, Musil C, Hirt R. Possibilities and limitations of molecular diagnostic methods in clinical microbiology: Feline immunodeficiency virus as an example. Wiener Tieraerztl Wochenschrift 2000;87:269-277.
27. Hartmann K, Donath A, Kraft W. AZT in the treatment of feline immunodeficiency virus infections, Part 1. Fel Pract 1995;23:16-21.
28. Zhang Y, Hatse S, De Clercq E, et al. CXC-chemokine receptor 4 is not a coreceptor for human herpesvirus 7 entry into CD4(+) T cells. J Virol 2000;74:2011-2016.
29. Egberink H, Borst M, Niphuis H, et al. Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proc Natl Acad Sci USA 1990;87:3087-3091.
30. Balzarini J, Hao Z, Herdewijn P, et al. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci USA 1991;88:1499-1503.
31. De Clercq E. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections. Intervirology 1997;40:295-303.
32. Andrei G, Snoeck R, Piette J, et al. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol Res 1998;10:523-531.
33. Del Gobbo V, Foli A, Balzarini J, et al. Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models. Antiviral Res 1991;16:65-75.
34. Calio R, Villani N, Balestra E, et al. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res 1994;23:77-89.
35. Knowles JO, Gaskell RM, Gaskell CJ, et al. Prevalence of feline calicivirus, feline leukaemia virus and antibodies to FIV in cats with chronic stomatitis. Vet Rec 1989;124:336-338.
36. Este JA, De Vreese K, Witvrouw M, et al. Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. Antiviral Res 1996;29:297-307.
37. Richardson J, Pancino G, Merat R, et al. Shared usage of the chemokine receptor CXCR4 by primary and laboratory-adapted strains of feline immunodeficiency virus. J Virol 1999;73:3661-3671.
38. Schols D, Claes S, De Clercq E, et al. AMD3100, a CXCR4 antagonist, reduced HIV virus load and X4 virus levels in humans. In: 9th Conference on Retroviruses and Opportunistic Infections, Seattle 2002; 53.
39. Troth SP, Hegedus LS. Effects of bicyclam on FIV infection in vivo. In: 7th International Feline Retrovirus Research Symposium (IFRRS). Pisa, Italy; 2004.
40. De Parseval A, Chatterji U, Morris G, et al. Structural mapping of CD134 residues critical for interaction with feline immunodeficiency virus. Nat Struct Mol Biol 2005;12:60-66.
41. Haschek WM, Weigel RM, Scherba G, et al. Zidovudine toxicity to cats infected with feline leukemia virus. Fundam Appl Toxicol 1990;14:764-775.
42. Hoover EA, Ebner JP, Zeidner NS, et al. Early therapy of feline leukemia virus infection (FeLV-FAIDS) with 9-(2-phosphonylmethoxyethyl)adenine (PMEA). Antiviral Res 1991;16:77-92.
43. Pisarev VM, Lee SH, Connelly MC, et al. Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication. Mol Pharmacol 1997;52:63-68.
44. AnorMED. Product information 2003. In:.
45. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37:1253-1262.
46. De Vreese K, Van Nerum I, Vermeire K, et al. Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120. Antimicrob Agents Chemother 1997;41:2616-2620.